<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107701">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02063763</url>
  </required_header>
  <id_info>
    <org_study_id>ITP0614</org_study_id>
    <nct_id>NCT02063763</nct_id>
  </id_info>
  <brief_title>TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.</brief_title>
  <acronym>ITP0614</acronym>
  <official_title>Use of TPO-mimetics to Prepare for Splenectomy in Adult Patients With Primary Immune Thrombocytopenia. Brooklyn Observational Retrospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at analyzing the therapeutic activity of TPO-mimetics Eltrombopag and
      Romiplostim as bridge therapy for splenectomy in adult patients with primary immune
      thrombocytopenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult immune primary thrombocytopenia is an autoimmune malignancy characterized by platelet
      destruction and inadequate platelet production. Its incidence is of three cases per 100,000
      people a year, with a prevalence in women in young and older adults.

      Splenectomy is, still today, the therapeutic approach that offers a bigger guarantee of a
      long term response (around 60+70%). Nevertheless, splenectomy may be accompanied by
      peri-operative complications in almost 10% of patients, which in rare cases may be fatal.
      These are normally hemorrhagic complications due to low platelet count. Thus, a previous
      therapy to increase platelets is advisable before any splenectomy.

      In patients who are refractory to corticosteroids and immunoglobulins or when its use is not
      indicated, splenectomy has a potential risk of more complications. Since the last few years,
      we count with TPO-mimetic drugs, specific for c-MPL receptor, able to stimulate platelet
      production, such as romiplostim and eltrombopag.

      Nowadays, TPO-mimetics are allowed in Italy when patients refuse splenectomy or when
      splenectomy is not contraindicated, but being ITP with a low platelet count (&lt;
      20-50.000/mmc) a potential contraindication to splenectomy due to hemorrhagic events, these
      drugs should be considered. Nevertheless, there are no data on therapeutic risks and safety
      of these agents when used for this indication. The aim of the present study is to verify, on
      an Italian national scale, the frequency of use, its impact and the safety profile.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Number of patients responding to TPO-mimetics</measure>
    <time_frame>Six months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>According to platelet count and presence or absence of hemorrhagic events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients on TPO-mimetics eltrombopag and romiplostim as bridge therapy before splenectomy.</measure>
    <time_frame>Six months.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and ways of administration.</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hemorrhagic events.</measure>
    <time_frame>At thirty days from splenectomy.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number and seriousness of hemorrhagic, thrombotic and infectious events at 30 days from splenectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicity.</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>No</safety_issue>
    <description>NCI CTCAE v. 4.0</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Adult Patients</condition>
  <condition>Immune Primary Thrombocytopenia</condition>
  <condition>Splenectomy</condition>
  <condition>TPO-mimetics</condition>
  <eligibility>
    <study_pop>
      <textblock>
        ITP adult patients having undergone splenectomy after a bridge therapy with eltrombopag or
        romiplostim.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent or chronic ITP in symtomatic phase.

          -  18 years of age or older.

          -  Indication for splenectomy due to refractory response to a previous therapy.

          -  Have used eltrombopag or romiplostim to increase platelet count before splenectomy.

          -  Have undergone splenectomy.

        Exclusion Criteria:

          -  No informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Zaja, Pr.</last_name>
    <role>Study Chair</role>
    <affiliation>Clinica Ematologica, DISM, Azienda Ospedaliera Universitaria S. M. Misericordia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrico Crea</last_name>
    <email>e.crea@gimema.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>U.O.C di Ematologia P.O. &quot;S.Giuseppe Moscati&quot;</name>
      <address>
        <city>Aversa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Caparrotti</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Caparrotti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Esposito</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Ematologia Ospedale &quot; Mons. Dimiccoli&quot;</name>
      <address>
        <city>Barletta</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Tarantini</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caterina Buquicchio</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margherita Giannoccaro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa) - Medicina Generale - Sezione di Ematologia - Ospedale Versilia USL 12 Toscana</name>
      <address>
        <city>Lido di Camaiore</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paola Lambelet</last_name>
    </contact>
    <investigator>
      <last_name>Paola Lambelet</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federico Simonetti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano</last_name>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariangela Greco</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Gabriella Mazzucconi</last_name>
    </contact>
    <investigator>
      <last_name>Maria Gabriella Mazzucconi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica - Policlinico Universitario</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Zaja</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Zaja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Verona - A. O. - Istituti Ospitalieri di Verona- Div. di Ematologia - Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dino Veneri</last_name>
    </contact>
    <investigator>
      <last_name>Dino Veneri</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Pizzolo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult patients</keyword>
  <keyword>Immune primary thrombocytopenia</keyword>
  <keyword>Splenectomy</keyword>
  <keyword>TPO-mimetics</keyword>
  <keyword>Eltrombopag</keyword>
  <keyword>Romiplostim</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
